Foamix Pharmaceuticals will solve all investors’ dermatological problems

On Thursday the major markets closed in green zone again. DJIA +0.73%, Nasdaq +0.57%, S&P500 +0.53%!

Biotech market also has raised: NASDAQ Biotechnology (NBI) +0.33%!

Shares of Prothena Corporation plc (PRTA) +5.02% and Foamix Pharmaceuticals Ltd (FOMX) +7.12% had raised. Shares of Immune Desi (IMDZ) -6.53% and XBiotech Inc. (XBIT) -15.49% had fallen!

Sage Therapeutic (SAGE) stocks increased $0.45 and closed at $6.77 (+7.12%).  The trading volume exceeded 5 times the average trading: 534K vs. 164K. The company's capitalization was $208M. The minimum FOMX share price: $5.48, while the maximum price: $12.20.

Foamix Pharmaceuticals Ltd. - pharmaceutical company focused on development and commercialization of medicines for dermatologic conditions in United States, Germany, France and Israel. The company was founded in 2003 and is based in Rehovot, Israel. Staff: 47 employees.

IVAO ratings:

Scientific Rating:  

Financial Rating:

Total Rating:

The rise of FOMX shares is associated with its oncoming financial report, which will be on 17 August. The analysts’ forecasts is EPS - $0.25.

Lead Foamix Pharmaceuticals’ products include FMX101 - a drug for topical application on the basis of minocycline foam for the treatment of moderate to severe acne, the drug has passed phase II clinical trials; and FMX102 - a drug for the treatment of impetigo, caused by staphylococcus aureus (complete phase II clinical trials). The company also develops FMX103 for the treatment of rosacea (phase II clinical trials); and FDX104 for the treatment of rash caused by chemotherapy (complete phase II clinical trials).

FOMX has collaboration and license agreements with Bayer HealthCare AG, Merz Pharmaceuticals, LLC, and Allergan PLC.

Foamix Pharmaceuticals’ revenue: 1.15M, EBITDA: -$18.32M, cash: $57M, debts: less than $1M.

Our forecast for stock price: $7.5.    

Learn how to invest in this company. Our experts will provide you all necessary support. Submit your application

You can order more detailed analysis on the company, which includes:

  • Analysis of financial performance

  • Overview of the market and competitors

  • Selection panel of experts on the drug and other drug companies

  • Estimation of prospects of following trials

Buy analytical review or contact our sales department:


Phone: +7 812 332 20 08

IVAO analysts: Andrew Voronkov, Ph.D., Alexander Novikov, MBA.  

Log in or sign up on  to add a comment to scientific problem you are interested in!
Comments (0)